Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

Emily K. Mader,1 Yoshihiro Maeyama,1 Yi Lin,2 Greg W. Butler,2 Holly M. Russell,1 Evanthia Galanis,1 Stephen J. Russell,1 Allan B. Dietz,2 and Kah-Whye Peng1

Abstract

Purpose: Preexisting antiviral antibodies in cancer patients can quickly neutralize oncolytic measles virus (MV) and decrease its antitumor potency. In contrast to “naked” viruses, cell-associated viruses are protected from antibody neutralization. Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used.

Experimental Design: Antimeasles antibody titers in ovarian cancer patients were determined. The protection of MV by MSC from antimeasles antibodies, the in vivo biodistribution profiles, and tumor infiltration capability of MSC were determined. Measles-naive or immune tumor-bearing mice were treated with naked virus or MSC-associated virus and mice survivals were compared.

Results: MSC transferred MV infection to target cells via cell-to-cell heterofusion and induced syncytia formation in the presence of high titers of antimeasles antibody, at levels that completely inactivated naked virus. Athymic mice bearing i.p. SKOV3ip.1 ovarian tumor xenografts passively immunized with measles-immune human serum were treated with saline, naked MV, or MV-infected MSC. Bioluminescent and fluorescent imaging data indicated that i.p. administered MSC localized to peritoneal tumors, infiltrated into the tumor parenchyma, and transferred virus infection to tumors in measles naïve and passively immunized mice. Survival of the measles-immune mice was significantly enhanced by treatment with MV-infected MSC. In contrast, survivals of passively immunized mice were not prolonged by treatment with naked virus or uninfected MSC.

Conclusions: MSC should be used as carriers of MV for intraperitoneal virotherapy in measles-immune ovarian cancer patients. (Clin Cancer Res 2009;15(23):7246–55)

Epithelial ovarian cancer is the most lethal of all gynecologic malignancies, killing >15,000 women in the United States each year (1). Due to the lack of effective screening modalities, the majority of patients present with advanced stage III disease at the time of diagnosis where the cancer still remains confined within the peritoneal cavity (2). Primary treatment is maximal debulking surgery followed by chemotherapy using carboplatin and paclitaxel or carboplatin alone (3). More than 75% of patients will eventually relapse, and salvage therapies for recurrent disease are not curative. Various novel biological therapeutics are being developed for the treatment of ovarian cancer; these include immunotherapy using tumor vaccines, monoclonal antibody (Ab) therapy, gene transfer of cytotoxic and antiangiogenic transgenes, and virotherapy using replication-competent tumor selective viruses (4–8).

We have been developing the Edmonston vaccine lineage of MV as a tumor selective oncolytic agent for cancer therapy (9). Oncolytic MV uses the hemagglutinin envelope glycoprotein to infect cancer cells via the cellular CD46 receptor and the fusion envelope glycoprotein to trigger fusion of the viral cell membranes for virus entry (10). Expression of these fusogenic hemagglutinin and fusion proteins on surfaces of virus-infected cells results in massive intercellular fusion with uninfected neighboring CD46-positive cells to generate the characteristic measles virus (MV)–induced cytopathic effects (CPE) of syncytia formation (11). We recently showed that overexpression of CD46 on cell surfaces results in the preferential killing of tumor cells (12, 13). Indeed, human ovarian cancer cells overexpress CD46 (14) and are highly susceptible to measles-induced CPE and cell killing (10, 12).

A phase I dose escalation clinical trial testing the safety of i.p. administration of 103 to 105 TCID50 of MV-CEA, a recombinant MV genetically modified to express a soluble marker...
Translational Relevance

Recombinant oncolytic measles viruses (MV) derived from the Edmonton vaccine lineage are undergoing phase I clinical testing in cancer patients. Although results from a recently completed trial testing i.p. administration of MV-CEA in patients with recurrent ovarian cancer indicated that MV-CEA was well tolerated, it is also apparent that virotherapy was suboptimal in these measles-immune patients. Here, we showed that human MSC could protect MV from neutralization by antiviral antibodies and serve as carriers to deliver MV to ovarian tumors. i.p. administered MSC trafficked to and colocalized with orthotopic OVCAR5, A2780, and SKOV3ip.1 human ovarian tumor xenografts in mice, enhancing contact of virus with the tumors. In addition, virus-loaded MSC transferred MV infection efficiently to ovarian tumor xenografts and significantly extended the survival of mice passively immunized with antimesales antibodies. Cell carriers should be incorporated in clinical trials using MV in ovarian cancer patients.

Virotherapy in Immune Mice Using MSC Cell Carriers

peptide to enable noninvasive monitoring of the profiles of viral gene expression, was recently completed (10, 15). The virus was well tolerated, and no dose-limiting toxicity was observed. There were, however, early indications of biological activity, especially in patients treated with higher doses of MV-CEA (16). As a possible follow-up trial using MV in ovarian cancer patients, we are exploring various strategies to improve delivery of MV to the tumor site, especially in patients with pre-existing anti-mesales antibodies. We and others have reported that cells can potentially be used as carriers to deliver oncolytic viruses to tumor xenografts in murine models, although only one study has evaluated the therapeutic activity of cell carriers given (intratumorally) to mice with preexisting antiviral antibodies (17–22). Potentially, any cell can be used as a virus carrier; for example, irradiated cell lines (20, 23), cytokine-induced killer cells (18), activated T cells (21), mesenchymal stem cell (MSC; ref. 24), and CD14+ monocyte–derived dendritic cells (25). MSCs are attractive as cell carriers because, in addition to their reported ability to home to tumors (26), adipose tissue–derived MSC are readily obtained from adipose tissues that are available as surgical wastes from gastric bypass or from fat biopsies. MSC can be expanded to large numbers in cellular therapy laboratories of medical centers under Good Laboratory Practice conditions, and clinical experience with infusion of MSC into humans is available (27). Here, we have chosen to test adipose tissue–derived MSC as a MV carrier in mice bearing orthotopic human ovarian tumor xenografts, focusing on their potential to overcome antiviral immunity in mice passively immunized with antimesales antisera.

Materials and Methods

Viruses, lentivectors, and cell lines. Recombinant Edmonton strain MV expressing firefly luciferase (FLuc), red fluorescent protein (RFP), green fluorescent protein (GFP), and sodium iodide symporter (NIS) were generated as described previously (28, 29). Viral titers were determined by TCID50 titration on Vero cells. To generate the lentivectors, 293T cells were cotransfected with gag-pol expression plasmid pCMV8.91, VSV.G envelope expression plasmid pMD-G, and vector plasmid encoding Gausia luciferase with an IRES linking cyan fluorescent protein (a kind gift from Dr. Bakhos A Tannous, Harvard Medical School, Cambridge, MA; refs. 30, 31). Vector supernatant was collected 48 h later, filtered (0.45 μm) and frozen at −80°C. Human ovarian cancer cell lines, SKOV3ip.1, stably expressing GLuc were maintained in MEM (Lonza) that was supplemented with 20% fetal bovine serum (FBS, Life Technologies), 100 μM Penicillin-streptomycin, and 2 mmol/L l-glutamine. Human ovarian cancer cell lines A2780 and OVCAR5 (kind gift from Dr. Viji Shridhar, Mayo Clinic, Rochester, MN) were maintained in 10% fetal bovine serum-DMEM. Adipose-derived MSC were maintained in Advanced MEM (Invitrogen) that was supplemented with 5% platelet lysate, 2 U/mL heparin, 100 U/mL penicillin-streptomycin, and 2 mmol/L l-glutamine. All media and growth supplements were purchased from Invitrogen.

Generation and characterization of MSC. Adipose tissue–derived MSC were generated as described. Briefly, fat tissue was mechanically dissected and disaggregated, cells were pelleted by centrifugation and left to adhere to plastic wells in media supplemented with a 5% solution of lysed human platelets. Typical cell recovery was 1.3 ± 0.68 × 10^6 cells/g of tissue (n = 7). These cells were phenotyped for typical MSC cell markers, and were negative for Class II, CD14, CD45, CD106, and positive for CD44, CD49d, CD71, CD73, CD90, CD105, CD166, and Class I. Phenotype of cells remained stable for more than seven passages and after cryopreservation. Cells were frozen in aliquots in liquid nitrogen and stored until use. Only low-passage cells (P5–7) were used for all the experiments of this study.

Virus infection assays. MSC were plated overnight in 6- or 12-well plates and MV-RFP at various multiplicities of infection (MOI, ratio of virus to cells) for 2 h at 37°C, after which the virus inoculum was removed, and the cells were cultured for 48 h in the presence or absence of a fusion inhibitory peptide (FIP, Z-D-Phe-Phe-Gly-OH; Bachem). Cells were trypsinized and the percentage of red fluorescent MV-RFP–infected cells was determined by flow cytometry. Numbers of viable cells were determined by trypan blue exclusion assay at various time points post infection.

Measles-immune human serum. Pooled human AB sera were purchased from Valley Biomedical, Inc. The antimesales Ab (IgG) titers of the sera were determined by the Mayo Clinic Serology Clinical Laboratory (Diamidex enzyme immunoassay). Antimesales Ab titers are reported as EU/mL. The corresponding full plaque reduction neutralization (PRN) titers of the sera were also determined (see below).

Virus neutralization assays. For the virus neutralization assays, ascites or sera were heat inactivated and diluted in Opti-MEM (2-fold serial dilutions) after which 100 to 250 TCID50/50 μL MV-GFP was added. The mixture was incubated at 37°C for 30 min after which Vero cells (7 × 10^3 cells/well/50 μL) were added and the mixture was plated in 96-well plates. The culture was maintained at 37°C for 2 d. Each dilution was done in triplicates, and the presence or absence of CPE in the wells was noted. The full PRN titer is the reciprocal of the highest dilution at which no CPE was noted in any of the replicate wells and before the dilution where CPE was observed in one or more wells.

Immunohistochemical staining for MV-N and CD68 proteins. Tumors were sectioned into halves and frozen immediately in optimal cutting temperature medium. Cryosections (5 μm thick) were aceton fixed for 10 min. The cryosections were permeabilized using 0.01% Triton X-100 and 5% horse serum for 15 min and incubated with biotinylated anti-MV nucleocapsid (MV-N) protein Ab (Mab 8906, Chemicon) for 1 h. The slides were developed using Vector ABC and alkaline phosphatase substrate kits (Vector Laboratories) and counterstained with Vector Nuclear Fast Red. For CD68 staining, aceton–fixed cryosections were incubated with biotinylated rat antimouse CD68

3 A. Dietz, unpublished data.
(Serotec) for 1 h. The slides were developed using Vector Elite ABC and DAB substrate kits (Vector Laboratories) and counterstained with Vector Hematoxylin QS.

**In vivo experiments.** All procedures involving animals were approved by and performed according to guidelines of the Institutional Animal Care and Use Committee of Mayo Foundation. To determine the half-life of human anti-measles Ab postpassive transfer into mice, athymic mice were given an i.p. injection of PBS-diluted measles-immune human serum. At 3 h (day 0), day 1, 2, 3, 4, 7, and 8 postserum infusion, mice were euthanized and bled, and the level of anti-MV neutralizing Ab titer in murine serum was determined by full PRN assay on Vero cells. The decrease in anti-MV Ab titer was plotted over time.

To establish various orthotopic models of human ovarian cancer, female athymic mice (5-6 wk of age; Taconic Laboratory) were injected with 2×10⁶ SKOV3ip.1 cells stably expressing Gaussia luciferase. The decrease in anti-MV Ab titer was plotted over time. 

Either 50 EU of measles-immune serum (measles immune) or saline was infused, micewere euthanized and bled, and the level of anti-MV neutralizing Ab titer in murine serum was determined by full PRN assay on Vero cells. The decrease in anti-MV Ab titer was plotted over time.

**Table 1.** Anti-measles IgG levels (EU/mL) and corresponding virus PRN titers in ascites fluids of ovarian cancer patients (n = 14)

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Anti-MV Ab titer</th>
<th>PRN titer</th>
</tr>
</thead>
<tbody>
<tr>
<td>OvCa12</td>
<td>26.10</td>
<td>64</td>
</tr>
<tr>
<td>OvCa9</td>
<td>38.40</td>
<td>8</td>
</tr>
<tr>
<td>OvCa8</td>
<td>54.30</td>
<td>2</td>
</tr>
<tr>
<td>OvCa2</td>
<td>75.70</td>
<td>N.d.</td>
</tr>
<tr>
<td>OvCa4</td>
<td>85.70</td>
<td>N.d.</td>
</tr>
<tr>
<td>OvCa5</td>
<td>86.00</td>
<td>N.d.</td>
</tr>
<tr>
<td>OvCa1</td>
<td>94.50</td>
<td>N.d.</td>
</tr>
<tr>
<td>OvCa10</td>
<td>102.80</td>
<td>32</td>
</tr>
<tr>
<td>OvCa3</td>
<td>108.00</td>
<td>N.d.</td>
</tr>
<tr>
<td>OvCa7</td>
<td>108.00</td>
<td>N.d.</td>
</tr>
<tr>
<td>OvCa6</td>
<td>110.00</td>
<td>N.d.</td>
</tr>
<tr>
<td>OvCa14</td>
<td>145.80</td>
<td>128</td>
</tr>
<tr>
<td>OvCa11</td>
<td>148.50</td>
<td>64</td>
</tr>
<tr>
<td>OvCa13</td>
<td>154.40</td>
<td>64</td>
</tr>
</tbody>
</table>

NOTE: A titer of >20 EU/mL is considered measles seropositive. Abbreviation: N.d., not done.
the neutralizing effects of anti-MV antibodies. At 1:4 serum dilution (69 EU/mL), 40% of infectious centers was present and at 1:16 dilution, the numbers of infectious centers were comparable with the control in which no serum was added. Hence, infected MSC were able to fuse with Vero cells and delivered MV infection to the target cells in an environment with a high amount of anti-MV antibodies.

Localization of MSC post i.p. administration into mice. Athymic mice were implanted i.p. with SKOV3ip.1 human ovarian cancer cells, and 7 d later, mice were injected i.p. with MV-Luc–infected MSC and imaged noninvasively for Fluc gene expression. FLuc signals were seen both in tumor-free and tumor-bearing mice given MV-Luc–infected MSC at day 1 post-MSC delivery (Fig. 3A). In the nontumor-bearing mice (top), the MV-Luc–infected cells were seen
at the injection site and at the omental region (highlighted by orange line). By day 3, the luciferase signals had decreased significantly and were undetectable by day 7 after death of the virus-infected MSC cells (Fig. 3A, top). In contrast, bioluminescent signals remained high and continued to increase over time in tumor-bearing mice given MV-Luc–infected MSC. It is evident that in tumor-bearing mice, the infected MSC were able to transfer MV-Luc infection to the peritoneal tumors. The infected tumors continued to propagate the virus, resulting in increase of Fluc bioluminescent signal even after death of the infected MSC (Fig. 3A). As expected, naked MV-Luc was highly efficient at infecting tumors in these measles naïve mice (Fig. 3A, bottom).

To determine if MSCs colocalized with the tumor nodules, another cohort of mice bearing intraperitoneal SKOV3ip.1, OVCAR5, or A2780 human ovarian tumors were injected i.p. with CellTracker Red CMTPX dye–labeled MSC (MV infected or uninfected). Tumors were harvested and examined directly under a fluorescence microscope 24 hours later. Abundant red fluorescent MSC were found at the omental tumor nodules and on smaller peritoneal tumor nodules that have seeded on the mesenteric linings or intestines (Fig. 3B). There was no apparent difference in the biodistribution of uninfected and infected MSC; both types of MSC were able to traffic to and localize on the tumors. Gross examination of the peritoneal cavity indicated that peritoneal tumor nodules in all three models of ovarian cancer were covered with red fluorescent MSC. In the OVCAR5 model in which there was significant coverage of the peritoneum wall by a cake of tumor cells, abundant MSC were found on the tumor cake (Fig. 3B). In contrast, the tumor-free peritoneal wall next to this tumor cake had minimal numbers of MSC (Fig. 3B). When given i.p. into control athymic mice with no tumor, MSC accumulated predominantly on the omentum (Fig. 3B). Cryosections of the peritoneal tumors were examined using confocal microscopy to determine the extent of MSC infiltration into the tumor parenchyma. At 4 and 24 hours postcell infusion, red fluorescent MSC were seen lining the surface of the tumor nodules and in the tumor parenchyma (Fig. 3C).

**Passive immunization of athymic mice with measles-immune serum.** Mice are not susceptible to infection by MV because they lack the CD46 receptor required for virus entry. Measles virus is also unable to replicate in murine tissues due to an intracellular block to transcription of viral genes (32, 33). Thus, we used the passive immunization method in which measles-immune human serum was injected i.p. into mice to generate measles-immune animals. We validated this method by giving athymic mice an i.p. injection of measles-immune human serum and measuring the level of neutralizing anti-MV antibodies present in the mouse sera at different time points. At 3 hours after i.p. injection of human serum (80 EU per mouse), the mice were confirmed to be measles-immune and the full PRN titers of the murine sera ranged between 64 and 512 (Fig. 4A). There was a gradual decrease in the PRN titers over the 1-week time interval. The estimated half-life of neutralizing antimesaives in the mice was 19.2 hours. In all subsequent experiments, virus or cell carrier delivery was done at 3 hours after i.p. infusion of this measles-immune pooled human serum.

**Antitumor efficacy in the presence of neutralizing antibodies.** Athymic mice were implanted with SKOV3ip.1-GLuc tumor cells, and 8 days later, mice received saline or equal numbers (1 × 10^6) of naked cell–free MV-Luc or MV-Luc–infected MSC. Mice were imaged noninvasively using bioluminescent imaging for GLuc expression with colenterazine substrate (tumor burden) and, the next day, for Fluc expression using D-luciferin substrate (viral gene expression). Imaging was done 1 day apart to ensure that all Gluc-bioluminescent signals had disappeared before Fluc imaging. We observed a good correlation between the location and intensity of GLuc and Fluc signals (Fig. 4B), indicating robust infection of the tumors by cell-free and MSC-associated virus in measles-naive animals. In measles-immune animals, the MV-Luc–infected MSC were able to transfer the infection to ovarian tumors, resulting in an increase in Fluc signal. In contrast, “naked” MV-Luc was neutralized by the anti-mesasives antibodies and the peritoneal tumors were not infected (Fig. 4B). Hence, delivery of MV is superior when MSC are used as virus carriers in measles-immune animals. The increase in Fluc signal in the tumors at day 7 was not due to presence of infected MSC. A significant portion of virus-infected MSC died by day 3 after i.p. delivery into mice resulting in complete loss of bioluminescent signals (Fig. 3A).

To investigate the antitumor activity of the various treatments, athymic mice were implanted i.p. with 2 × 10^6 SKOV3ip.1-GLuc tumor cells, and 8 days later, mice were passively immunized by i.p. administration of measles-immune human serum (50 EU) or given saline. Three hours later, mice were given equal numbers
(1 × 10^5) of cell-free MV-NIS or MV-infected MSC i.p. The MV/MSC had been loaded with MV-NIS by incubation with virus at MOI of 4.0 for 2 hours (~60% infection; Fig. 1) and washed once in PBS. In the measles-immune groups, MV-NIS and MV/MSC were subsequently incubated in vitro with measles-immune serum (50 EU) for 30 min at 37°C before injection into the animals to ensure neutralization of any surface-bound virus. Thus, each measles-immune mouse received a total of 100 EU of anti-MV IgG Ab.

The Kaplan Meier survival curves of the mice were plotted (Fig. 5). The median survival for saline control was 31 days (n = 5 mice), uninfected MSC was 31 days (n = 5 mice), MV (-Ab) was 64 days (n = 12 mice), MV (+Ab) was 31 days (n = 12 mice), MV/MSC (-Ab) was 62 days (n = 10 mice), and MV/MSC (+Ab) was 66 days (n = 11 mice). All mice in the saline, uninfected MSC, and MV (+Ab) groups (22 of 22) were euthanized because they developed bloody ascites (3-4.5 mL), with extensive dissemination of ovarian tumors in the peritoneal cavity, perigastric area, and on the peritoneal side of the diaphragm. In contrast, only a few of the mice in the MV (-Ab) or MV/MSC groups (+Ab and - Ab) developed ascites (6 of 33). Several of the mice appeared jaundiced and were euthanized (12 of 33). Examination at necropsy indicated tumor obstruction/constriction around the gall bladder or bile duct. The rest of the animals were euthanized due to weight loss of >20%, or development of an ulcerated subcutaneous tumor at the injection site toward the end of the study.

**Fig. 3.** In vivo distribution of MSC after i.p. delivery. A, serial bioluminescent imaging of mice after i.p. injection of MV-Luc–infected MSC (MV/MSC) into mice with no tumor or mice bearing intraperitoneal human SKOV3ip.1 ovarian tumors. Another group of tumor-bearing mice received MV-Luc (MV) B, MV-infected MSC were labeled with a fluorescent CellTracker Red CMTPX dye and injected i.p. into mice bearing peritoneal SKOV3ip.1, A2780, or OVCARS human ovarian tumors. Mice were euthanized 24 h later. Photographs (×40 or ×100 magnification) of freshly harvested tissues showing red fluorescent MSCs on the omentum or peritoneal wall of mice with no tumor or on the tumor nodules of mice. C, confocal microscopy images of tumor cryosections demonstrating presence of red fluorescent MSC on the surface and in the parenchyma of SKOV3ip.1 tumors. Scale bars, 100 μm unless otherwise indicated.
The survival curves of the respective treatment groups were compared against the saline control and the \( P \) values were determined (Fig. 5A). Uninfected MSC did not have any antitumor activity against human ovarian cancer, survival of these mice was not significantly different from the saline-treated group (\( P = 0.92 \)). As expected, MV-NIS (-Ab) significantly extended the survival of mice compared with saline control (\( P < 0.0001 \)). However, the antitumor activity of MV-NIS was negated in passively immunized mice. Thus, there was a significant difference in survival outcome using naked MV-NIS in measles-naïve mice versus measles-immune mice (\( P < 0.0001 \)). In contrast to therapy using cell-free virus, treatment of passively immunized mice with MV-infected MSC significantly extended the survival of mice (\( P < 0.0001 \), doubling the median survival from 31 days (MV-NIS +Ab) to 66 days for MV/MSC +Ab. Furthermore, there was no significant difference in therapy using MV/MSC in measles naïve or measles-immune animals (\( P = 0.93 \)). The presence of preexisting anti-measles antibodies did not diminish the delivery and transfer of MV from infected MSC. We did not observe a significant difference in survival of measles-naïve mice treated with MSC-associated MV compared with cell-free virus (\( P = 0.67 \)).

Cryosections of omental tumors harvested at necropsy were immunostained with an Ab specific for the measles nucleocapsid (MV-N) protein and CD68, a macrophage marker. As shown in Fig. 5B, MV-N-positive areas were found in MV-NIS (-Ab), MV/MSC (-Ab), and MV/MSC (+Ab) tumors but not in MV-NIS (+Ab) tumors. Staining for CD68+ macrophages indicated abundant infiltration of phagocytic macrophages into the MV-infected tumors, either surrounding or in necrotic areas or colocalizing with the MV-N-positive areas. It is likely that the macrophages are phagocytic in nature, as suggested by the abundance of CD68 staining in the necrotic areas of the tumors (see black arrow in MV/MSC +Ab tumor). There were also areas of MV-N staining with no corresponding CD68 staining (e.g., last panel, MV/MSC +Ab tumor).

**Discussion**

The Edmonston vaccine strain of MV is capable of inducing tumor-selective destruction of ovarian cancer cells while sparing normal cells in the peritoneal cavity (10, 11). However, many ovarian cancer patients have preexisting anti-measles antibodies. As a strategy to protect oncolytic MV from neutralizing antiviral antibodies and improve delivery of the virus to peritoneal tumors, we evaluated the potential of adipose tissue–derived MSC for delivery of MV to orthotopic human ovarian tumors after i.p. administration in passively immunized mice.

A major potential of advantage of using cells as carriers for delivery of viruses to tumors is protection of the oncolytic virus from antiviral antibodies. In addition, carrier cells can also interact dynamically with the host by responding to chemokines secreted by tumors and may preferentially accumulate at tumor sites. In contrast, systemically administered viruses are sequestered rapidly by the reticuloendothelial system of the liver and spleen and become unavailable for circulation to the tumor. Virus-infected cells may also serve as in situ virus production factories, thereby increasing the numbers of infectious virus available in the tumor microenvironment. The “ideal” cell carrier should be susceptible to virus infection or be able to “carry” the virus on/in the cell, remain viable for a sufficient period of time postinfection to transfer the virus, and be able to support virus replication/progeny production (19, 21, 34). However, there are also disadvantages associated with cell
In the case of MV, infection of a nontransformed cell such as MSC required larger amounts of virus (high MOI; MOI, 4.0) to obtain significant numbers (60%) of infected cells. Also, the clinical protocol incorporating cell carriers becomes more complex as it may involve harvest of autologous cells from the patients, expansion of the cells, and preloading of the cells with virus in a GLP cell processing facility. In addition, the trafficking profile of the cell carrier needs to be taken into consideration. Ex vivo expanded cells such as T cells, MSC, and dendritic cells tend to arrest in the lungs, liver, and spleen after intravascular infusion in experimental animals and humans (21, 25, 35, 36), although Power and Bell (37) recently determined that leukemic cell carriers were not so readily trapped in the lung vasculature and could deliver oncolytic vesicular stomatitis virus to tumors.

Autologous T cells, irradiated tumor cells, bone marrow–derived MSC, dendritic cells, and endothelial progenitor cells have been used to deliver oncolytic viruses to tumor xenografts (38). Coukos et al. (39) first showed the feasibility of using a human ovarian teratocarcinoma line PA-1 cell line for HSV-1716 virotherapy of ovarian cancer. PA-1 cells were preirradiated at 20 Gy before herpes simplex virus infection, after which cells were injected i.p. into athymic mice with peritoneal ovarian tumors. Irradiated PA-1 cells colocalized with tumor xenografts to result in significant enhancement in survival of tumor-bearing mice compared with nontreated controls or virus alone. Hamada et al. (40) were among the first to show that cell carriers can protect oncolytic viruses from neutralizing antiviral antibodies. Tumor cell carriers (A549 lung carcinoma) infected with a conditionally replicating adenovirus were irradiated before direct intratumoral injection into subcutaneous ovarian tumors in immunized syngeneic mice. Interestingly, treatment of virus-immune mice with cell carriers resulted in superior efficacy and complete tumor regressions compared with nonimmunized mice. Hamada et al. (40) suggested that superior antitumor activity could be due to induction of antiadenoviral and antitumoral CTL responses in the preimmunized animals. Bone marrow–derived MSC have been used successfully for delivery of oncolytic adenoviruses for the treatment of ovarian cancer or glioma xenografts (22, 24). They showed that mesenchymal progenitor cells infected by RGD displaying adenoviral vector homed to preestablished ovarian tumor nodules and extended the survival of tumor-bearing mice, although the feasibility of MSC to overcome antiviral antibodies was not addressed.

Due to previous debulking surgeries, ovarian cancer patients typically have extensive amounts of adhesions that could significantly hinder i.p. distribution of the virus after i.p. delivery. In addition, fluids injected into the peritoneal cavity rapidly drain of the cavity via the diaphragmatic stomata into the lymphatics, and from the mediastinal lymph node into the vascular system (41, 42). In contrast, i.p. administered MSC home to and localize on ovarian nodules in the peritoneal cavity of mice. Indeed, abundant MSC were seen “covering” the omental tumor nodules with minimal MSC in the omentum. In non-tumor-bearing mice, i.p. injected MSC trafficked to and localized on the omentum instead. The omentum is an extension of the mesothelium that becomes drawn out and folded on itself during development and contains abundant milky spots, which consist predominantly of resident peritoneal macrophages (42, 43). Cancer cells injected i.p. into experimental animals preferentially home to, infiltrate, and engraft at the omentum (44, 45). As such, it is ideal that MSC appear to have a tropism for the omentum and tumor nodules, thus improving virus delivery to the tumor cells. The mechanism(s) that determines MSC tropism for tumors have not been fully elucidated, but it is clear...
that signaling molecules produced by the tumor cells (e.g., stromal cell–derived growth factor SDF-1, monocyte chemotactic protein MCP-1, vascular growth factor) and adhesion molecules (e.g., ICAM-1, integrins, and L-selectin) contribute to MSC tumor homing and engraftment (46–48).

Immunohistochemical staining revealed areas of MV gene expression in tumors from MV-NIS–treated (−Ab), MV/MSC–treated (−Ab), and MV/MSC–treated (+Ab) animals but not in tumors from MV-NIS–treated (+Ab) mice, confirming that the superior survival of mice required active viral replication and gene expression. Uninfected MSC did not have antimacrophage activity. Abundant infiltrates of CD68-positive macrophages were found in the measles-infected areas/tumors but minimal in uninfected tumors. The role of macrophages in the measles-infected tumors remains to be determined. They could be phagocytic macrophages whose role is to clear up nonviable virus-infected tumor cells as indicated by necrotic areas with negative/minimal MV-N staining but abundant CD68 staining. On the other hand, there were also areas where MV-N and CD68 staining overlapped. Chiocca and colleagues (49) proposed that CD68 macrophages, as part of the host innate immune response, inhibit virotherapy by restricting the intratumoral spread of oncolytic viruses. They have elegantly shown that addition of cyclophosphamide, an immunosuppressive agent, to oncolytic herpes virus therapy resulted in decreased numbers of infiltrating CD68 macrophages, increased intratumoral viral replication, and superior survival of mice (50). Certainly, research into optimal ways to combine cyclophosphamide with measles virotherapy in ovarian cancer is needed; for example, the timing of drug administration is important as cyclophosphamide (an alkylating agent) may negatively impact the viability of cell carriers.

In contrast to studies using vaccinia or adenoviruses (24, 51), we did not observe an enhancement in the oncolytic activity of MV when using cell carriers compared with free virus in mice

Disclosure of Potential Conflicts of Interest

S.J. Russell and K.W. Peng are named inventors on patents owned by Mayo Clinic regarding oncolytic measles that have been licensed to a biotechnology company (NISCO).

Acknowledgments

We thank the Mayo Clinic Women’s Cancer Program (Drs. Kimberly Kalli and Vij Shridhar) for the assays samples and cell lines and Dr. Bahk and A. Tannous (Harvard Medical School, Cambridge, MA) for the kind gift of Gaussia luciferase expression plasmid.

References

24. Peng KW, Facteau S, Wegman T, O’Kane D,
Virotherapy in Immune Mice Using MSC Cell Carriers


Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

Emily K. Mader, Yoshihiro Maeyama, Yi Lin, et al.


**Updated version**
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-09-1292

**Cited articles**
This article cites 52 articles, 12 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/23/7246.full.html#ref-list-1

**Citing articles**
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
/content/15/23/7246.full.html#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.